Learn More
In this paper an analysis of the presence and possibilities of altmetrics for bibliometric and performance analysis is carried out. Using the web based tool Impact Story, we collected metrics for 20,000 random publications from the Web of Science. We studied both the presence and distribution of altmetrics in the set of publications, across fields, document(More)
An extensive analysis of the presence of different altmetric indicators provided by Altmetric.com across scientific fields is presented, particularly focusing on their relationship with citations. Our results confirm that the presence and density of social media altmetric counts are still very low and not very frequent among scientific publications, with(More)
This paper analyzes Altmetric.com, one of the most important altmetric data providers currently used. We have analyzed a set of publications with DOI number indexed in the Web of Science during the period 2011-2013 and collected their data with the Altmetric API. 19% of the original set of papers was retrieved from Altmetric.com including some altmetric(More)
Introduction Mendeley is a popular social reference manager with currently about 2.8 million users and 535 million user documents (Haustein & Larivière, 2014). Mendeley helps users to organize scientific documents in private libraries but at the same time publishes aggregated readership counts per documents to indicate their popularity among Mendeley users.(More)
In this study, the 'academic status' of users of scientific publications in Mendeley is explored in order to analyse the usage pattern of Mendeley users in terms of subject fields, citation and readership impact. The main focus of this study is on studying the filtering capacity of Mendeley readership counts compared to journal citation scores in detecting(More)
OBJECTIVE The current standard option for iron chelation therapy (ICT) in transfusion-dependent patients with beta-thalassemia is deferoxamine (DFO). We aimed to compare the compliance with DFO vs. deferasirox (Exjade®), a novel oral iron chelator, in patients with transfusion-dependent beta-thalassemia. METHODS In this cross-sectional study, 220 patients(More)
BACKGROUND The problem of iron-overload observed in thalassemia patients can be overcome using chelating agents such as deferiprone (Ferroprox(®) ), deferasirox (Exjade(®) ) and deferoxamine (Desferal(®) ). Although these drugs can be used as monotherapy, combined therapy, especially deferiprone with deferoxamine, has led to promising outcomes in various(More)